Venlafaxine Hydrochloride

Migraine, Panic Disorder, Migraine Disorders + 7 more
Treatment
5 FDA approvals
20 Active Studies for Venlafaxine Hydrochloride

What is Venlafaxine Hydrochloride

VenlafaxineThe Generic name of this drug
Treatment SummaryVenlafaxine (Effexor) is a type of antidepressant medication called a serotonin-norepinephrine reuptake inhibitor. It works by blocking the transporters responsible for reabsorbing serotonin and norepinephrine, leaving more of the neurotransmitters available in the brain. Venlafaxine is approved to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. It can also be used to prevent migraine headaches, reduce menopause symptoms, and manage neuropathic pain, although there is limited evidence that it is effective for this condition.
Effexoris the brand name
image of different drug pills on a surface
Venlafaxine Hydrochloride Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Effexor
Venlafaxine
1993
725

Approved as Treatment by the FDA

Venlafaxine, also known as Effexor, is approved by the FDA for 5 uses such as Hot Flashes and Breast Cancer .
Hot Flashes
Helps manage Vasomotor Symptoms Associated With Menopause
Breast Cancer
Helps manage Breast Cancer
Depression
Breast Cancer
Helps manage Breast Cancer
Vasomotor Symptoms Associated With Menopause
Helps manage Vasomotor Symptoms Associated With Menopause

Effectiveness

How Venlafaxine Hydrochloride Affects PatientsVenlafaxine is a medication used to treat depression and other mental disorders. It works by increasing the amount of certain chemicals in the brain that are responsible for mood regulation. Venlafaxine does not cause any additional effects on the body's other systems.
How Venlafaxine Hydrochloride works in the bodyVenlafaxine is used to treat various mental health conditions. It works by increasing the amount of serotonin and norepinephrine at the synapse, which are the gaps between nerve cells. It does this by blocking the reuptake, or recycling, of these neurotransmitters. It primarily affects serotonin, but can also affect norepinephrine and dopamine with higher doses.

When to interrupt dosage

The measure of Venlafaxine Hydrochloride is contingent upon the diagnosed ailment, including Social Anxiety Disorder, Neuropathic Pain and Vasomotor Symptoms Associated With Menopause. The quantity of dosage is contingent upon the method of delivery (e.g. Tablet or Tablet - Oral) noted in the table beneath.
Condition
Dosage
Administration
Panic Disorder
, 75.0 mg, 150.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 100.0 mg, 225.0 mg
Capsule, extended release, Oral, , Capsule, extended release - Oral, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule, coated, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, coated, extended release
Migraine Disorders
, 75.0 mg, 150.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 100.0 mg, 225.0 mg
Capsule, extended release, Oral, , Capsule, extended release - Oral, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule, coated, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, coated, extended release
Breast Cancer
, 75.0 mg, 150.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 100.0 mg, 225.0 mg
Capsule, extended release, Oral, , Capsule, extended release - Oral, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule, coated, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, coated, extended release
Postmenopause
, 75.0 mg, 150.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 100.0 mg, 225.0 mg
Capsule, extended release, Oral, , Capsule, extended release - Oral, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule, coated, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, coated, extended release
Depression
, 75.0 mg, 150.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 100.0 mg, 225.0 mg
Capsule, extended release, Oral, , Capsule, extended release - Oral, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule, coated, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, coated, extended release
Hot Flashes
, 75.0 mg, 150.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 100.0 mg, 225.0 mg
Capsule, extended release, Oral, , Capsule, extended release - Oral, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule, coated, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, coated, extended release
Migraine
, 75.0 mg, 150.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 100.0 mg, 225.0 mg
Capsule, extended release, Oral, , Capsule, extended release - Oral, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule, coated, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, coated, extended release
Generalized Anxiety Disorder
, 75.0 mg, 150.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 100.0 mg, 225.0 mg
Capsule, extended release, Oral, , Capsule, extended release - Oral, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule, coated, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, coated, extended release
Social Anxiety Disorder
, 75.0 mg, 150.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 100.0 mg, 225.0 mg
Capsule, extended release, Oral, , Capsule, extended release - Oral, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule, coated, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, coated, extended release
Neuropathic Pain
, 75.0 mg, 150.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 100.0 mg, 225.0 mg
Capsule, extended release, Oral, , Capsule, extended release - Oral, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, Capsule, coated, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, coated, extended release

Warnings

Venlafaxine Hydrochloride Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Venlafaxine may interact with Pulse Frequency
There are 20 known major drug interactions with Venlafaxine Hydrochloride.
Common Venlafaxine Hydrochloride Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethanol
Major
Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Hydroxyzine.
Iobenguane
Major
The therapeutic efficacy of Iobenguane can be decreased when used in combination with Venlafaxine.
Methylene blue
Major
Venlafaxine may increase the serotonergic activities of Methylene blue.
Venlafaxine Hydrochloride Toxicity & Overdose RiskThe lowest toxic dose of venlafaxine in rats was 350 mg/kg for female rats and 700 mg/kg for male rats. Those who overdose on venlafaxine may feel sleepy, experience numbness or tingling in the extremities, dizziness, confusion, nausea, vomiting, low blood pressure, seizures, irregular heartbeat, liver damage, and even death. There is no known remedy for venlafaxine overdose, and symptoms may be managed without or with treatment, hospitalization, and activated charcoal. Studies have also shown that the risk of fatal outcomes from venlafaxine overdose is higher
image of a doctor in a lab doing drug, clinical research

Venlafaxine Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Venlafaxine Hydrochloride?

Currently, 1038 studies are being conducted to explore the potential of Venlafaxine Hydrochloride for the management of Neuropathic Pain, prophylaxis of migraine headaches and Vasomotor Symptoms Associated With Menopause.
Condition
Clinical Trials
Trial Phases
Depression
216 Actively Recruiting
Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1, Early Phase 1
Panic Disorder
14 Actively Recruiting
Not Applicable
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable
Neuropathic Pain
4 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Migraine
51 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Breast Cancer
22 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Migraine Disorders
1 Actively Recruiting
Phase 3
Social Anxiety Disorder
16 Actively Recruiting
Not Applicable
Hot Flashes
4 Actively Recruiting
Not Applicable, Phase 2, Phase 1
Generalized Anxiety Disorder
7 Actively Recruiting
Not Applicable, Phase 2, Phase 3

Venlafaxine Hydrochloride Reviews: What are patients saying about Venlafaxine Hydrochloride?

5Patient Review
8/10/2022
Venlafaxine Hydrochloride for "Change of Life" Signs
Venlafaxine has been an absolute godsend. I was experiencing hot flashes every fifteen minutes--to the point where it was disrupting my work life-- and this medication has helped to completely alleviate that problem. It's also helped with some of my anxiety symptoms, which is a huge plus. I'm very grateful to have found this medication!
5Patient Review
8/26/2022
Venlafaxine Hydrochloride for Depression
I've only been on this for a day, but I already feel so much better. For the first time in a long time, I didn't have any negative thoughts or feelings throughout the day. It's truly a godsend.
5Patient Review
9/18/2022
Venlafaxine Hydrochloride for Repeated Episodes of Anxiety
This drug has been working great for me in terms of managing my anger.
3.7Patient Review
8/13/2022
Venlafaxine Hydrochloride for Depression
I'm only on my second week taking this medication, and I am already experiencing a lot of the listed side effects. I'm hoping that they will go away soon. Does anyone have any suggestions?
1.7Patient Review
6/27/2022
Venlafaxine Hydrochloride for Panic Disorder
Terrible, I was out of it everyday and still having panic attacks
1Patient Review
10/14/2022
Venlafaxine Hydrochloride for Major Depressive Disorder
This treatment was an absolute nightmare for me. It caused severe apathy, lack of creativity, and insomnia. Furthermore, I felt like I was going insane 24/7. I would not recommend this drug to anyone.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about venlafaxine hydrochloride

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is venlafaxine hydrochloride used for?

"Venlafaxine is a medication used to treat depression, anxiety disorders, and panic disorders. Venlafaxine is part of a class of drugs called serotonin and norepinephrine reuptake inhibitors (SNRIs)."

Answered by AI

Is venlafaxine a strong antidepressant?

"The doctor may prescribe Effexor for other conditions besides the standard ones it is meant for. One study found that it was an effective antidepressant. However, each person's reaction and tolerance to the medicine may be different."

Answered by AI

Is venlafaxine same as Xanax?

"Effexor XR is a serotonin and norepinephrine reuptake inhibitor (SNRI) and Xanax is a benzodiazepine.

Do Effexor XR and Xanax serve the same purpose? Effexor XR (venlafaxine hydrochloride extended-release) and Xanax (alprazolam) are both used to treat patients with panic and anxiety disorders. Effexor XR is also used to treat patients with major depressive disorders. However, Effexor XR and Xanax belong to different drug classes. Effexor XR is a serotonin and norepinephrine reuptake inhibitor (SNRI) while Xanax is a benzodiazepine."

Answered by AI

What are the side effects of venlafaxine hydrochloride?

"... , Sickness (vomiting)

If you are feeling nauseous, try taking venlafaxine with or after a meal. To help with sweating and hot flushes, wear loose clothing and use a fan where possible. If you are having headaches, rest and drink plenty of fluids. A dry mouth is another common side effect. If you are feeling dizzy or sleepy, try to lie down and relax. Some people also have trouble sleeping when taking this medication. Constipation is another possible side effect. Lastly, some people may vomit."

Answered by AI

Clinical Trials for Venlafaxine Hydrochloride

Image of University of Rochester Medical Center in Rochester, United States.

Deaf CBT-TS for Suicide Risk

18+
All Sexes
Rochester, NY
The goal of this clinical trial is to learn if a short, Zoom-based intervention, Cognitive Behavioral Therapy for Treatment-Seeking for Deaf Individuals (Deaf CBT-TS) can change beliefs about mental health treatment and increase treatment-seeking behaviors in Deaf adults with untreated mental health or alcohol use problems. It will also see if Deaf CBT-TS may reduce suicide risk and explore factors that may increase the effectiveness of Deaf CBT-TS. The main questions it aims to answer are: * Does Deaf CBT-TS increase positive beliefs about treatment and increase treatment-seeking behaviors? * Does Deaf CBT-TS increase hope and reduce mental health symptoms, suicide ideation, and alcohol use? * Is Deaf CBT-TS more effective for individuals with less cultural stress compared to those with high levels of cultural stress? * Is Deaf CBT-TS more effective for Deaf individuals in residential areas with more Deaf resources than those with less Deaf resources? Researchers will compare individuals who complete Deaf CBT-TS to those on a waitlist to see if Deaf CBT-TS works to increase positive beliefs about treatment and treatment-seeking behaviors. Participants will: * Complete a baseline assessment including demographic information, measures of hope, general mental health and functioning, alcohol use, suicide ideation, cultural stress, and beliefs about treatment. * Receive Deaf CBT-TS (2 sessions) or be placed on a waitlist with the option of receiving Deaf CBT-Ts after 4 months * Complete two follow-up assessments in 2 and 4 months.
Waitlist Available
Has No Placebo
University of Rochester Medical Center
Image of Washington University School of Medicine in St Louis, United States.

Supplemental Imaging for Breast Cancer

25 - 55
Female
St Louis, MO
Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.
Waitlist Available
Has No Placebo
Washington University School of MedicineTabassum Ahmad, M.D.
Image of St. Joseph's Healthcare Hamilton in Hamilton, Canada.

Psychotherapy for Depression

18 - 65
Female
Hamilton, Canada
The RESPOND trial explores the link between early life adversity and later life depressive symptoms. The investigators have designed a new psychological therapy tailored to address the symptoms that can be caused by difficult experiences in early life. These symptoms include low mood, emotional dysregulation, and distressing thoughts and beliefs related to difficult or traumatic experiences. The investigators would like to see if this new therapy helps people feel better. The investigators are also studying the biological changes that can occur as a result of early life adversity, and how this therapy may influence those changes. To do this, The investigators ask questions about participants' physical and mental health and take blood samples.
Recruiting
Has No Placebo
St. Joseph's Healthcare HamiltonSheryl Green, PhD
Have you considered Venlafaxine Hydrochloride clinical trials? We made a collection of clinical trials featuring Venlafaxine Hydrochloride, we think they might fit your search criteria.Go to Trials
Image of Altasciences in Mount Royal, Canada.

Elinzanetant for Hot Flashes

18 - 65
Female
Mount Royal, Canada
The aim of this study is to examine the relative bioavailability of elinzanetant when administered in new oral formulations (treatment B and C) after both single and multiple oral doses, compared to its administration in soft gel capsule form (treatment A). Study details include: An ambulatory screening visit within 4 weeks prior to first treatment. Participants will be admitted to the ward on Day -1 of each period. On Day 1, either treatment B or treatment C will be administered fasted in the evening, followed by blood sampling for a 24-hour pharmacokinetic (PK) profile. On Day 2, the multiple dosing starts 3 hours after a standardized dinner in the evening. After the last dosing on Day 7, a complete PK profile for 24 hours will be collected. If there are no medical objections, participants will be discharged from the study ward on Day 9 in the morning for a washout-out period of at least 10 days (240 hours after last dosing, after period 1 and 2) or, in period 3, after the follow-up examination. The total duration of the study will be approximately 10 to 12 weeks for each participant.
Phase 1
Recruiting
AltasciencesBayer
Image of Baylor College of Medicine in Houston, United States.

Stepped Care Treatment for Anxiety

7 - 17
All Sexes
Houston, TX
Childhood anxiety disorders (CAD) are common and impairing. Family based cognitive behavioral therapy (CBT) is efficacious in treating CAD. Yet, many children do not receive care due to barriers such as limited provider availably, high treatment costs, and constrained family resources (e.g., time). To combat these barriers, other treatment methods have been developed. The stepped care treatment models maximize resources by providing low-intensity, low-cost interventions as a first time treatment, while stepping up care for those needing more intensive treatment. Specifically, a stepped care model for CAD that begins with a parent-focus intervention has great promise to deliver efficacious and cost-effective treatment without having to engage the child. While stepped care approaches show promise in treating CAD with comparable efficacy to standard CBT, there remains a large research-to-practice gap. The stepped care model for CAD that begins with a parent-focused intervention has yet been explored, and very little is known about intervention mediators that explain mechanisms of change. This research is being done to improve the reach and quality of services using a stepped care model, offering an affordable and practical solution to the widespread gap in youth mental health care.
Waitlist Available
Has No Placebo
Baylor College of Medicine
Have you considered Venlafaxine Hydrochloride clinical trials? We made a collection of clinical trials featuring Venlafaxine Hydrochloride, we think they might fit your search criteria.Go to Trials
Image of MUSC Brain Stimulation Lab in Charleston, United States.

High-Dose tDCS for Depression

18 - 70
All Sexes
Charleston, SC
In this study, investigators are testing whether a higher dose of a non-invasive brain stimulation technique, called transcranial direct current stimulation (tDCS), can be safely used in people with depression. Participants will come to the Brain Stimulation Lab and receive mild electrical stimulation through electrodes placed on their scalp. The study begins with a safety run-in, where the first few participants will receive stimulation at gradually increasing levels (2, 4, and 6 milliamps) while being closely monitored. If no serious side effects are found, later participants will receive repeated 6 milliamp sessions for 5 days total. Investigators will check skin comfort, mood, and overall tolerability after each session.
Recruiting
Has No Placebo
MUSC Brain Stimulation LabClayton Olash, MD
Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Waitlist Available
Has No Placebo
Johns Hopkins MedicineRisheng Xu, MD, PhDMedtronic
Image of Detroit Recovery Project in Detroit, United States.

Peer-Delivered Behavioral Activation for Depression

18+
All Sexes
Detroit, MI
Low-income individuals have limited access to evidence-based interventions for mental health. Peer recovery specialists, individuals in recovery from mental health and/or substance use problems, have the potential to increase access to evidence-based interventions for individuals from low-resource communities, particularly when trained and supervised in models that are acceptable and feasible in these communities. This study will examine the effectiveness and implementation potential of a peer-delivered evidence-based intervention (Behavioral Activation) among individuals receiving services from a community-based treatment setting providing integrated physical and behavioral healthcare.
Waitlist Available
Has No Placebo
Detroit Recovery Project
Have you considered Venlafaxine Hydrochloride clinical trials? We made a collection of clinical trials featuring Venlafaxine Hydrochloride, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security